Breaking a paradigm: IL-6/STAT3 signaling suppresses metastatic prostate cancer upon ARF expression

Zoran Culig; Jan Pencik; Olaf Merkel; Lukas Kenner

doi:10.1080/23723556.2015.1090048

Breaking a paradigm: IL-6/STAT3 signaling suppresses metastatic prostate cancer upon ARF expression

Mol Cell Oncol. 2016 Apr 4;3(2):e1090048. doi: 10.1080/23723556.2015.1090048. eCollection 2016 Mar.

Authors

Zoran Culig¹, Jan Pencik², Olaf Merkel², Lukas Kenner³

Affiliations

¹ Department of Urology, Medical University of Innsbruck , Innsbruck, Austria.
² Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria.
³ Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria; Unit of Pathology of Laboratory Animals (UPLA), University of Veterinary Medicine Vienna, Vienna, Austria.

Abstract

Interleukin 6 (IL-6)/signal transducer and activator of transcription 3 (STAT3) signaling is considered to have important oncogenic functions in prostate cancer (PCa). However, a recent study highlighted the central role of IL-6/STAT3 signaling in regulation of the ARF-MDM2-p53 senescence axis. This reversal of the postulated oncogenic properties of IL-6/STAT3 signaling in PCa has important therapeutic implications.

Keywords: ARF; CDK4/CDK6 inhibitors; IL-6; Metastasis; Prostate cancer; STAT3; Senescence.